Overview

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Multicenter, prospective, non-controlled study in a pediatric cohort (<6 years-old) with severe Von Willebrand Disease (VWD).
Phase:
Phase 4
Details
Lead Sponsor:
Grifols Therapeutics LLC
Instituto Grifols, S.A.
Collaborator:
Instituto Grifols, S.A.
Treatments:
Factor VIII